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Introduction: Synthetic cannabinoids (SCs) are a class of synthetic chemicals with cannabis-like 
properties, and little is known about their pharmacological and toxicological effects. This objective of this 
study was to explore the effects of SCs and the underlying motivations of use among subjects with lived 
experiences. Methods: Content analysis of experiences of people using SCs was carried out based on online 
discussions. A total of 1660 posts from 50 threads between 2004 and 2016 were examined. Results: 
Relevant information was recorded on characteristics of users as well as on characteristics of SCs, the 
modality of their use, and the SC-related experienced effects and toxicity. Conclusions: Users exchanged 
online significant information on SCs consumption. While a growing amount of attention has been given to 
the chemical and pharmacological profile of SCs, very little is known about the subjective components of 
such use. It remains fundamental to study the lived experiences of people who used novel psychoactive 
substances (NPSs) to implement prevention and treatment, and to guide future research in the field. 
 














Synthetic cannabinoids (SCs) are a class of novel psychoactive substances (NPSs) that have similar 
effects to cannabis despite having a different structure from 9-tetrahydrocannabinol (THC), the main 
psychoactive ingredient in cannabis (Elsohly et al. 2014; Schifano et al. 2019; Tung, Chiang & Lam 2012). 
SCs are often available as single or multiple synthetic substances sprayed onto herbal material or plants 
(Wells & Ott 2011). The drugs are usually marketed under various names relating to ‘herbal incense’ or 
‘plant food’  (Gunderson et al. 2012; Winstock & Barratt 2013). Reasons for taking SCs include curiosity, 
relaxation, change in perception, mood and cognition, the possibility to avoid drug tests, and their legal 
status (Castellanos et al. 2011; Vandrey et al. 2012; Winstock & Barratt 2013). 
Whereas THC is a partial CB1 receptor agonist, most SCs are full agonists of the CB1 receptor, and 
their effects are not limited by the dose response relationship (Papanti et al. 2013; Schifano et al. 2019). 
Subsequently, the increased affinity for CB1 receptors results in higher potency and greater adverse effects, 
including anxiety, agitation, drowsiness, hallucinations, hypertension, tachycardia, paranoia, poor 
coordination, respiratory depression and seizures (Adamowicz et al. 2017; Auwarter et al. 2009; Castaneto 
et al. 2014; Castellanos et al. 2011; Cooper 2016; Hermanns-Clausen et al. 2013; Papanti et al. 2013; 
Schneir, Cullen & Ly 2011; Zawilska & Wojcieszak 2014). SCs are associated with more adverse effects 
and increased emergency department admission than many other NPSs (Gummin et al. 2018; Spaderna, 
Addy & D'Souza 2013), and can have a negative impact on the treatment course for  substance-related 
withdrawal and craving symptoms (Prilutskaya et al. 2017). 
Despite the above concerns, there are limited studies regarding the effects and toxicity associated 
with SCs based on the perspective of people with lived experiences. Moreover, most of the information 
available regarding the effects of SCs arises from admissions to emergency departments or treatment 
centres, likely resulting in incomplete data. Therefore, this work aims to explore the effects and toxicity of 





A qualitative study of online discussion fora was conducted to explore users’ knowledge and 
experience of the effects and toxicity of SCs. Data were retrieved from five key discussion fora that had 
been previously identified by the Psychonaut Web Mapping Project (Deluca et al. 2012). After inspecting 
each discussion forum thoroughly, 128,000 threads were retrieved of which 50 threads (1660 posts) were 
found relevant to the objectives of the study. Hence, a thread was  made of multiple posts whereas each post 
comprised a single entry in a thread. All of the included threads were in English. 
The study was conducted in accordance with the ethical standards as laid down in the 1964 
Declaration of Helsinki and its later amendments or comparable ethical standards. Ethical approval was 
obtained from the Bournemouth University Internal Ethics Committee (ID 20840). Although the 
information collected in this study was already available in the public domain, anonymity was ensured in 
all online discussion by giving each thread a number and removing any users’ data that could hint 
identities/nicknames. No posts or contribution to the discussion fora were made, and no data were shared 
outside the remits of the study. 
Threads were saved as PDFs and subjected to conventional content analysis (Bilgrei 2016; Kassai 
et al. 2017; Soussan & Kjellgren 2014). Data in threads were initially coded independently by two 
investigators to minimise bias. The threads were then read carefully, line-by-line, and subthemes/themes 
reflecting key concepts were identified. After the threads were coded, investigators met to discuss any 
discrepancies among codes, to cluster codes into themes, and to discuss potential relationships among the 
constituted categories. Five broad themes were obtained: characteristics of users, characteristics of SCs, use 
of SCs, wanted effects related to SCs, and toxicity/adverse effects related to SCs. The inter-rater reliability 
of the themes was appraised by postulating the threads to a third researcher. Threads and codes were 
provided to the researcher without the themes. The inter-rater reliability for the final themes was 95%, which 
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suggested the validity of the coding methodology. To evaluate the quality of the threads a checklist made 
up of a series of questions was adapted from (Robinson 2001) (Appendix A). In addition, the information 
from the threads was validated by matching the interpretations with findings from clinical reviews regarding 




As mentioned above, the analysis of online discussion fora related to SCs yielded 50 relevant threads 
with 1660 posts. These threads were combined into five main themes: characteristics of users, characteristics 
of SCs, use of SCs, wanted effects related to SCs, and toxicity/adverse effects related to SCs (Table 1). 
 
3.1 Characteristics of users 
 
Analysis of the threads identified 540 people with lived experiences of SCs from 36 different 
countries, with the majority of posts coming from the United States (n=296), the United Kingdom (n=88), 
Australia (n=58) and Canada (n=34). Only 68 of them reported their age, of which 65 were adult (between 
18- and 64-years-old), and three were minors (n=2) or elderly (n=1). One-hundred-eleven (111) users 
reported their gender (97 males and 14 females). 
The major reason for which users took SCs were: passing a drug test (n=51), unavailability of 
cannabis (n=20), cheaper price compared to cannabis (n=11), no legal consequences from taking SCs (n=6), 
and stronger effects of SCs with shorter half-life (n=3). 
 
3.2 Characteristics of synthetic cannabinoids 
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A total of 81 different derivatives were reported from 1053 posts (Table 2). The reported derivatives 
belonged to seven different subclasses, among which indole and indazole-based SCs were the most 
common. Indole-based derivatives were the most frequently mentioned, with 46 derivatives reported 716 
times. The main indole-based derivatives encountered were AM2201 (n=125), JWH018 (n=107) and 
UR144 (n=66). Also, 22 different indazole-based derivatives were reported 220 times. The most commonly 
mentioned indazole-based derivatives were 5F-AKB48 (n=63), AB-FUBINACA (n=42) and THJ018 
(n=35). The frequency of the reports on the SC derivatives was not related to the time they have been on 
the market but was rather attributable to the unique subjective effects associated with the SC (Table 3).  
Four-hundred-seventy-five users reported using 148 different blends of SCs. The most commonly 
mentioned blends were Spice, K2, Mr Kosh and Kronic (Table 4). Spice was the most prevalent blend and 
was used by 80 users; Spice was labelled as a mixture containing varying SCs, among which AM2201, 
CP47497, HU210, JWH derivatives, JWH018, JWH019, JWH073 and JWH122. K2 was used by 45  users; 
derivatives of JWH (including JWH018 and JWH073) were defined by some users as the main ingredients 
in K2. Mr Kosh and Kronic were used by 33  and 32  users respectively; the SC derivatives in Mr Kosh 
were not reported, while Kronic was stated to contain JWH or AM derivatives with JWH018 being the main 
ingredient. All the remaining blends were used by 10 users or less. 
One-hundred-fifty-seven users reported the source they had purchased the drug from. The main 
sources were the Internet and street headshops, that were mentioned by 65 and 62 users respectively. Other 
sources for SCs were gas stations (n=10), off-license shops (n=6), adult shops (n=4), bookshops (n=2) and 
street markets (n=1). 
 
3.3 Use of synthetic cannabinoids 
 
Two main subthemes emerged in relation to SCs use: route of administration and polydrug use. The 
most widely used route of administration of SCs was smoking (n=540), followed by oral administration 
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(n=99). Additional routes encountered were sublingual (n=7), nasal insufflation (n=5), intravenous (n=3) 
and rectal (n=2). Details are given in Table 5. 
Users experienced the combination of SCs with other drugs: antipsychotics, opioid analgesics, 
hallucinogens, stimulants and depressants. These combinations ranged from two to five substances; yet, the 
exact doses and effects of such combinations were note provided in detail. Users sought caffeine (n=2), 
tobacco (n=13), cannabis (n=4), unspecified NPSs (n=2) or other SCs (n=40) in order to intensify the 
psychedelic effects, increase the duration of effects or resist the urgency to re-dose. Only one antipsychotic 
combination was reported and involved mixing a SC (ABFUBINACA) with aripiprazole and 
chlorprothixene. Four users reported mixing SCs with opioids: one user did not specify the opioid and three 
reported codeine (with dextromethorphan in two cases). In addition to dextromethorphan, four other users 
combined SCs with psychedelics: 4-acetoxy-N,N-dimethyltryptamine, ketamine, methoxetamine and an 
unspecified psychedelic. Additional combinations of SCs included alcohol (n=17) or benzodiazepines 
(n=5), mainly in order to mask the SC effects, to counteract SC-induced panic attacks, and to increase 
depressant effects. 
 
3.4 Wanted effects 
 
Users mainly sought SCs to improve mood, escape reality or relax. The major psychological effects 
reported by users were psychedelic effects (n=93). The JWH series was considered the ‘strongest for 
tripping’, alongside 5FPB22, 5FABPINACA, ABPINACA, AM2201 and UR144. The choice of SCs was 
also influenced by the dose, route of administration and modality of intake of the drug (e.g. certain users 
recommended a dose above 5 mg to start the visual hallucinations, while other users recommended the 
combination of several SCs, among which 5AKB48 and STS135, in a smoking mixture to have a more 
intense tripping effect). The tripping effect was reported as equivalent to that induced by ketamine and 
phencyclidine derivatives. 
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Users were also interested in the relaxation (n=82) and sedative (n=23) effects induced by SCs. SCs 
were found to be more calming, healing and relaxing than natural cannabis. SC-related euphoria (n=38) was 
described as ‘extreme’, ‘pleasant’ and ‘surreal’. The duration of the euphoric effect varied markedly 
between 20 min and up to 6 h. Euaphoria was associated with uncontrollable intense laughter, which was 
reportedly associated with elevated mood (n=10), mental clarity (n=7) and music appreciation (n=10). Such 
effects on euphoria were reported to be more intense than those of cannabis. 
 SCs were considered by users as mood stabilisers, mood enhancers, antidepressants and/or as 
substances able to fill the room with happiness. SCs were reported to increase users’ alertness, creativity, 
insight and sociability. The duration of the effects varied between person but was generally described as 
short (3 min to 3 h). Most users experienced rapid effects, with an onset within 5 min; yet, some users did 
not see onset until 7 h. 
 
3.5 Toxicity and adverse effects 
 
Toxicity and adverse effects reported by users involved the nervous, cardiovascular, respiratory, 
gastrointestinal, hepatic and renal systems. 
Nervous system adverse effects: SCs reportedly induced alteration in perception (n=82) and in 
behaviour (n=24), anxiety (n=147), paranoia (n=83), psychosis (n=22), depression (n=19), and addiction 
(n=92). This included dissociation, auditory, zooptic and visual hallucinations, tachyphagia, aggression, 
hyperactive thoughts, irritability, social withdrawal, and antisocial behaviour. In rare cases, users 
experienced psychopathological episodes related to schizophrenia and bipolar disorder after using SCs. 
When compared to cannabis, effects of SCs were described as shorter acting but more addictive. In extreme 
cases, loss of consciousness and passing out was seen among users. Users reported having frequent panic 
attacks and blackouts related to the use of SCs: some of them reportedly suffered convulsion prior to 
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blackouts, fell on the floor, tried to crawl, then eventually passed out and woke up with ‘face down in 
vomit’. 
Cardiovascular adverse effects: The main cardiovascular adverse effects experienced by users were 
tachycardia (n=53), hypertension (n=5) and palpitations (n=6). Less reported cardiovascular adverse effects 
included cardiac irregularities, cardiac damage and cardiac arrest. 
Respiratory adverse effects: Respiratory adverse effects included bronchitis (n=3; it was described 
as severe and comparable to lung cancer), chest pain (n=17; it included difficulty in breathing and it was 
associated with anxiety, shortness of breath, numbness and coughs), coughing (n=12; some users reported 
‘bad coughs’ described as extreme and horrid, yielding black/dark mucus on many occasions.), dyspnoea 
(n=27) and respiratory irritation (n=15; it was described as chemical burns to lungs associated with throat 
burns and, in some instances, it was compared to a mustard attack).  
Gastrointestinal adverse effects: Gastrointestinal adverse effects experienced by users included 
general gastrointestinal irritations, with abdominal pain, abdominal cramps, nausea, vomiting and diarrhoea. 
Gastrointestinal adverse effects were described as intense, strong and of long duration (up to seven days 
after smoking). 
Hepatic and renal adverse effects: Users experienced hepatic and renal adverse effects that included 
liver damage (n=10; it was described as direct, extreme and painful), increased urination (n=3), and kidney 
damage (n=11; this was sometimes associated with pain lasted more than one week) that occasionally 
exacerbated to kidney failure (n=2) that could be lethal. 
SCs-drug interactions: When SCs were mixed with other SCs, users experienced more intense 
tripping, anxiety, depression, psychosis and tachycardia. Effects encountered when SCs were mixed with 
opioids included tremors, tachycardia, respiratory disturbances and liver damage. One user warned against 
mixing SC with codeine and dextromethorphan as it resulted in drug-induced psychosis. Depressants were 
reported to counteract the panic attacks of SCs, yet users experienced negative effects after using 
depressants with SCs including nausea, vomiting, sweating and severely depressed breathing. Moreover, 
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mixing stimulants and depressants caused “couch lock”, “munchies” and dry mouth. Mixing SCs with 
psychedelics resulted in more intense effects, tripping, seizures and loss of consciousness. 
Overdose: Overdose related to SCs use was reported by 63 users and involved multiple organ 
toxicity. The doses of individual SCs were not always specified but were stated to range between 1 and 300 
mg. Main reactions included anxiety, difficulty in breathing, palpitations, paranoia, tachycardia, tremors 
and loss of motor control. Other symptoms seen as a result of overdose were tachycardia, palpitations, 
hypotension, vomiting and difficulty in breathing. 
Withdrawal symptoms: Withdrawal symptoms experienced after stopping SCs included anxiety, 




Previous studies related to SCs have mainly relied on quantitative data from emergency department 
admission, psychiatric clinics  or questionnaire surveys (Adamowicz et al. 2017; Gummin et al. 2018; 
Hermanns-Clausen et al. 2013; Higgins et al. 2019; Le Boisselier et al. 2017; Loeffler, Delaney & Hann 
2016; Vandrey et al. 2012). There are only two qualitative studies that have explored the toxicity and harm 
reduction of such NPSs using online discussion fora (Kronstrand et al. 2013; Thayer & Ray 2006), which 
were limited to discussion fora of a single country (Sweden and Norway). Hence, the present study 
contributes to the literature through directly exploring the users’ experience and knowledge regarding the 
use, effects and toxicity of SCs via content analysis of online discussions among individuals from several 
different countries. 
The specific results of the study are summarized in Tables 1-5. Several findings are consistent with 
previous evidence. The users of online discussion fora were mainly males, with a self-reported median age 
of 29-years-old. This was also found in observational studies conducted in psychiatric hospitals (Heltsley 
et al. 2012; Loeffler, Delaney & Hann 2016; Vandrey et al. 2012), and could be related to the fact that (i) 
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males have been described as more likely to use illicit drugs than females (Center for Behavioral Health 
Statistics and Quality 2017; European Monitoring Centre for Drugs and Drug Addiction 2019; Kikura-
Hanajiri et al. 2013) and more prone to share their drug experience or seek treatment (European Monitoring 
Centre for Drugs and Drug Addiction 2005), and (ii) Internet use is higher among young adults than among 
middle-aged and older adults (Kikura-Hanajiri et al. 2013). The main motivation to take SCs for the online 
users was the possibility to get high while passing a drug test; such motivation for SC use was found to be 
relevant also in several previous reports, summarized by Loeffler et al (Loeffler, Delaney & Hann 2016). 
The most popular SCs among users were AM2201 and JWH018, which  have been identified in previous 
reports as popular derivatives due to their psychedelic  effects (Gunderson et al. 2012; McQuade et al. 
2013).  
The most commonly reported blends were Spice and K2, as also observed in other studies on the 
topic (Corazza et al. 2014; Kjellgren, Henningsson & Soussan 2013; Schneir, Cullen & Ly 2011). 
Consistently with previous research (Ashton et al. 2008; Pertwee 2006), the most common wanted effects 
experienced with SCs reported by users were euphoria, relaxation and psychedelic effects; these effects are 
mainly caused by activation of the CB1 receptors, which can result in increased or decreased release of  
monoamines (Auwarter et al. 2009; Banerjee, Snyder & Mechoulam 1975; Kendall & Yudowski 2016; 
Steffens & Feuerstein 2004; Szabo & Schlicker 2005). Analgesia was reported by several users after 
consuming the drug, and many clinical studies have focused on the use of SCs as analgesic agents (Ashton 
et al. 2008; Every-Palmer 2011; Fattore & Fratta 2011). 
 Users reported adverse effects associated with SCs in relation to multiple systems, including the 
psychiatric, cardiovascular, respiratory and gastrointestinal systems. Psychiatric effects included anxiety, 
paranoia, sedation, addiction, psychosis, aggression and depression. Psychotic relapses resulting from the 
use of SCs were identified in previous studies(Schifano et al. 2019); notably, Papanti et al. have coined the 
term “spiceophrenia” in order to highlight how SCs can trigger the onset of acute psychosis in vulnerable 
individuals and/or the exacerbation of psychotic episodes in those with a previous psychiatric history with 
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increased impact compared to natural cannabis (Papanti et al. 2013). The respiratory toxicity reported by 
users was characterised as difficulty breathing, chest pain and coughing, which is in line with previous 
findings (Cooper 2016; Küçük et al. 2016); surprisingly, in the present study users experienced respiratory 
adverse effects even after oral use of SCs, this possibly being related with redistribution of SCs to the lungs. 
The present study has several limitations, among which: (i) as the research was retrospective, it was 
not always possible to attain all the desired information regarding drugs used, uses, doses and duration of 
action of SCs, and therefore the reported identity of derivatives was not confirmed my any other means; (ii) 
missing information from threads could influence the results; (iii) there was no method to verify the 
subjective experience of users; (iv) no biological validation (such as hair testing) was conducted. However, 
the use of Internet as a source of information can also be considered a strength, as Web monitoring 
represents a unique opportunity for understanding users’ point of view about the effects of drugs: writing 
in a Web forum allows the user to hide his/her identity and to comment without any hesitation. This is 
particularly useful in the case of SCs, where there has been only a limited number of animal and human 
studies focused on adverse effects after the failure of clinical trials in the 1950s. The use of the Internet has 
been performed extensively in the research on addiction over the last decade (Corazza et al. 2013; Davey et 
al. 2012), and the present study provides data (summarized in Tables 1-5) based on users’ personal 
experiences that contribute to increase our understanding of different aspects of the phenomenon of SC use.  
It is difficult to evaluate whether the results of the study are representative to SC users in general or 
specific to those considered as  “e-psychonauts”, i.e. individuals highly connected to Web sources with high 
levels of general and pharmacological knowledge of substances (Davey et al. 2012). However, the present 
study provides information on SCs arising from individuals who experienced them, with this contributing 
to increase our understanding of the SC-use phenomenon. Lived experiences are important for the 
development of clinical guidance as well as for our research, and should be taken into consideration when 
addressing research, clinical and political interventions (e.g. harm reduction interventions) on substance-
related issues. Future studies are encouraged which include analyses of SC-related effects correlating lived 
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experiences with other sources (such as data from toxicology and poison centres) in order to obtain a more 
detailed and reliable knowledge of the substances. 
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Table 1. Main themes and subthemes emerging from the study 
Theme Subtheme Quotation 
Characteristics 
of users 
Passing a drug test Many of “us” are subject to harsh and random drug testing,  
that doesn’t test for synthetics, as a condition of our employment. 
Unavailability of cannabis I tried a few times with a friend from high school when we couldn't  
get a decent dealer for weed 
 14 
Price Availability and Price would be the main two reasons for me 
No legal consequences  
of taking SCs 
One of the other advantages was you didn’t have to associate 
them (synthetic cannabinoids) with criminal element. 
Characteristics 
of SCs 
Derivatives The most traditional was AM2201. AM2233 was good to me 
Blends Spice was a mixture containing CP47,497, JWH019 and HU210 
Sources Plenty of sites sell it online, a simple google search will help you find it 
Use of SCs Route of administration In the past, I would mix 1 gram of JWH-122 into 1L of  
Vegetable oil and make some pretty awesome brownies . . .  
around 10 mg/brownie of 122 would do the trick 
Polydrug use I also found both this combination and oral 5FAKB48 more psychedelic  
than smoked or oral AKB48. The combination of smoking 5FAKB48  
and STS135 even though more potent, also gives me more  
of an uncomfortable feeling and more of a, for me, unwanted buzz. 
SCs: wanted 
effects 
Psychedelic  Much more psychedelic than natural cannabinoids 
Relaxing But I do like the 'relaxing plateau' you get for an hour or so afterwards 
Sedative  I really enjoyed that heavy sedating/physical effects 
Euphoric Experience with pure JWH018 got me to a headspace  





Alteration in perception Time felt extremely slow; I'd say about 3-times slower than  
normal… as if space and time were altered, so a definite disconnect going  
on in perception. 
Alteration in behaviour You will become antisocial, violent, won't give a s*** about others 
Anxiety Too much anxiety is felt at higher doses 
Paranoia Because they are so much strongerm the JWHxxx compounds can produce  
a more intense version of weed paranoia 
Psychosis Taking syn noid resulted in me experiencing an acute psychotic reaction  
first time I ever heard voices inside my head 
Depression I feel depressed and anxious afterwards several days. 
Addiction Shorter acting, more intense hence more addictive…  
 
I got withdrawals now after smoking approximately 300 mg daily of various  
synth 'noids…Synth ‘noids are certainly very addictive, and can cause  
bad withdrawals after a heavy binge. 
Tachycardia I was sure that my heart was going to just rip out of my chest it was beating 
so hard and so fast 
Bronchitis The effects…sounded like I had lung cancer and coughed up 
 big chunks of grey/black/green/yellow s***, which my doctor  
called chronic bronchitis. 
Chest pain Comes with chest pain, feeling short on breath 
Cough I got such a terrible cough when I was smoking them 
Dyspnoea Also, I've experienced severly depressed breathing 
Liver damage I've got the start of a cyst on my liver from smoking them 
SCs-drug interactions 
 
Overdose Overdoses on synthetic cannabinoids are a terrible feeling.  
I've had six or seven, and I always end up in the foetal position  
with uncontrollable tremors 
Withdrawal symptoms Withdrawal after smoking a half g for  months was worse than benzos or opiates 
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Table 2. SC derivatives reported by users 
Derivative Synonyms Chemical Name Chemical Formula Mwt. N 
Indole 
AM-2201 FUBIMINA, JWH2201 1-[(5-Fluoropentyl)- 
1H-indol-3-yl] -(naphthalen-1-yl) 
methanone 
C24H22FNO 359.44 125 
JWH-018 AM-678, JWH 018 Naphthalen-1-yl- 
(1-pentylindol-3-yl)methanone 
C24H23NO 341.45 107 





C21H29NO 311.461 66 
JWH-073 Spice Naphthalen-1-yl- 
(1-butylindol-3-yl) methanone 
C23H21NO 327.42 38 
JWH-250 No information 2-(2-methoxyphenyl)- 
1-(1-pentylindol-3-yl) ethanone 
C22H25NO2 335.439 37 
JWH-122 No information (4-methyl-1-naphthyl)  
-(1-pentylindol-3-yl)methanone 
C25H25NO 355.472 32 
JWH-210 No information 4-ethylnaphthalen-1- 
yl-(1-pentylindol-3-yl)methanone 
C26H27NO 369.498 32 




-indol-3-yl) (4-methyl-1- naphthalenyl)- 
methanone 
C25H24FNO 373.462 30 
XLR-11 5F-UR-144 (1-(5-fluoropentyl)- 
1H-indol-3-yl) (2,2,3,3-  
tetramethylcyclopropyl)methanone 
C21H28FNO 329.46 29 
5F-PB-22 5F-QUPIC, 5-fluoro-PB-22, 
 QCBL-2201, MN-25F,  
QUPIC N-(5-fluoropentyl)  
analogue 
1-pentyfluoro-1H- 
indole-3-carboxylic acid 8- quinolinyl  
ester 
C23H21FN2O2 376.42 24 
MMB-Chminaca MDMB-CHMICA Methyl (2S)-2-{[1- 
(cyclohexylmethyl)-1H-indol-3-yl] 
formamido}-3,3-dimethylbutanoate 
C23H32N2O3 384.52 20 
STS-135 5F-Apica N-(adamantan-1-yl)-1- 
(5-fluoropentyl)-1H-indole-3-  
carboxamide 
C24H31FN2O 382.51 19 
2NE1 SDB-001, APICA N-(1-adamantyl)-1- 
pentyl-1H-indole-3-carboxamide 
C24H32N2O 364.522 16 
AM-2233 No information 1-[(N-methylpiperidin- 
2-yl) methyl]-3-(2-iodobenzoyl) 
indole 
C22H23IN2O 458.334 16 
BB-22 QUCHIC 1-(cyclohexyl methyl)- 
1H-indole-3-carboxylic acid 8-  
quinolinyl ester 
C25H24N2O2 384.47 13 
JWH-081 No information 4-methoxynaphthalen- 
1-yl- (1-pentylindol- 3-yl)methanone 
C25H25NO2 371.47 13 
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PB-22 QUPIC 1-Pentyl-1H-indole-3- 
carboxylic acid 8-quinolinyl ester 
C23H22N2O2 358.43 10 





C26H26FNO 387.488 8 
JWH-200 WIN 55,225 (1-(2-Morpholin-4- 
ylethyl) indol-3-yl)-naphthalen-1-  
ylmethanone 
C25H24N2O2 384.469 7 
JWH-203 No information 2-(2-chlorophenyl)-1- 
(1-pentylindol-3-yl) ethanone 
C21H22ClNO 339.858 7 
NM-2201 CBL-2201 naphthalen-1-yl 1- 
(5-fluoropentyl)-1H-indole-3-  
carboxylate 
C24H22FNO2 375.4 7 
AM-694 No information 1-[(5-fluoropentyl)- 
1H-indol-3-yl] -(2-iodophenyl) 
methanone 
C20H19FINO 435.273 6 
FUB-PB-22 No information quinolin-8-yl 1-[(4- 
fluorophenyl) methyl]-1H- 
indole-3- carboxylate 
C25H17FN2O2 396.41 6 
JWH-019 No information 1-hexyl-3-(naphthalen- 
1-oyl) indole 
C25H25NO 355.471 6 
AB-001 No information 1-pentyl-3-(1-adamantoyl) 
indole 







C22H25NO 319.44 4 




C26H26N2O 382.497 3 




C24H26N2O6 438.472 3 
JWH-182 No information (1-pentyl-1H-indol-3-yl)  
(4-propyl-1-naphthalenyl)-  
methanone 
C27H29NO 383.5 3 
WIN-55,212-2 No information (11R)-2-methyl-11-[(morpholin-4-yl) 
 methyl]-3- (naphthalene-1-carbonyl)-9- 
oxa-1-azatricyclo [6.3.1.0]  
dodeca-2,4(12),5,7-tetraene 
C27H26N2O3 426.52 3 
AB-FUBICA No information N-[(1S)-1-(Aminocarbonyl)- 
2-methylpropyl]-1-[(4- fluorophenyl) 
 methyl]-1H-indole-3-carboxamide 
C21H22FN3O2 367.42 2 
ADBICA ADB-PICA N-(1-Amino-3,3- 
dimethyl-1-oxobutan-2-yl)- 
1-pentyl-1H-indole-3-carboxamide 
C20H29N3O2 343.46 2 
FDU-PB-22 No information naphthalen-1-yl 1- 
[(4-fluorophenyl) methyl]-1H-indole- 
3-carboxylate 
C26H18FNO2 395.42 2 




C21H23NO2 321.413 2 
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RCS-8 SR-18, BTM8 2-(2-methoxyphenyl)-1- 
[1-(2-cyclohexylethyl) indol-3- yl]  
ethanone 
C25H29NO2 375.503 2 
5F-JWH-018 5F-AB-001, 5-fluoro  
JWH 018 adamantyl  
analog, AM2201  
adamantyl analogue 
[1-(5-fluoropentyl)-1H- 
indol-3-yl] tricyclo [3.3.1.13,7]- 
dec-1-yl-methanone 
C24H30FNO 367.5 1 
5F-MN-24 5F-NNE1, 5F-NNEI 1-(5-Fluoropentyl)-N- 
(naphthalen-1-yl)-1H-indole-3-  
carboxamide 
C24H23FN2O 374.45 1 
A-796,260 LTI-258 [1-[2-(4-morpholinyl)  
ethyl]-1H-indol-3-yl] (2,2,3,3-  
tetramethylcyclopropyl)- 
methanone 
C22H30N2O2 354.5 1 
A-834,735 No information [1-[(tetrahydro-2H- 
pyran-4-yl) methyl]-1H-indol-3-yl]  
(2,2,3,3-tetramethylcyclopropyl)- 
methanone 
C22H29NO2 339.5 1 
AB-005 No information [1-[(1-methyl-2- 
piperidinyl) methyl]-1H-indol-3-yl]  
(2,2,3,3-tetramethylcyclopropyl)- 
methanone 
C23H32N2O 352.51 1 




C21H23N3O2 349.4 1 




C22H24FN3O2 381.45 1 
AM-1248 No information 1-[(N-methylpiperidin- 
2-yl) methyl]-3-(adamant-1-oyl)  
indole 
C26H34N2O 390.561 1 
JWH-180 No information (1-propyl-1H-indol-3-yl)  
(4-propyl-1-naphthalenyl)-  
methanone 
C25H25NO 355.5 1 
JWH-201 No information 2-(4-methoxyphenyl)-1- 
(1-pentyl-1H-indol-3-yl)-  
ethanone 
C22H25NO2 335.4 1 




C23H26N2O3 378.5 1 
Indazole 
5F-AKB48 5F-APINACA N-(adamantan-1-yl)-1- 
(5-fluoropentyl)-1H- 
Indazole-3-carboxamide 
C23H30FN3O 383.5 63 
AB-Fubinaca Ab-fubi N-[(2S)-1-amino-3- 
methyl-1-oxobutan-2-yl]-1- 
[(4- fluorophenyl) methyl]  
indazole-3-carboxamide 
C20H21FN4O2 368.4 42 
THJ-018 JWH018 indazole analogue 1-naphthalenyl(1- 
pentyl-1H-indazol-3-yl)- 
methanone 
C23H22N2O 342.4 35 
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AKB48 APINACA N-(1-adamantyl)-1- 
pentyl-1H-indazole-3- 
carboxamide 
C23H31N3O 365.51 19 




C20H28N4O2 356.46 17 
THJ-2201 No information [1-(5-Fluoropentyl)-1H- 
indazol-3-yl] (1-naphthyl) 
methanone 
C23H21FN2O 360.42 14 
AB-PINACA No information N-[(1S)-1-(aminocarbonyl) 
-2-methylpropyl]-1-pentyl- 
1H-indazole-3-carboxamide 
C18H26N4O2 330.43 9 
AFUBINACA AKB48 N-(4-fluorobenzyl)  
analogue,  






C25H26FN3O 403.5 3 




C23H21FN2O2 376.4 2 




C22H21FN4O 376.4 2 




C21H30N4O2 370.5 2 
MN-18 No information N-(naphthalen-1-yl)-1- 
pentyl-1H-indazole-3-  
carboxamide 
C23H23N3O 357.5 2 




C20H28FN3O3 377.46 1 











C19H26FN3O3 363.43 1 






C22H26FN3O 367.5 1 




C21H24N4O2 364.4 1 




C21H23FN4O2 382.43 1 
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ADSB-FUB-187 No information 7-chloro-N-[(2S)-1- 
[2-(cyclopropylsulfonylamino)  
ethylamino]-3,3-dimethyl-1- 
oxobutan-2-yl]-1-[(4- fluorophenyl)  
methyl] indazole-3-carboxamide 
C26H31ClFN5O4S 564.07 1 
APP-Fubinaca No information N-[(1S)-2-amino-2-oxo- 
1-(phenylmethyl) ethyl]-1-[(4-  
fluorophenyl) methyl]-1H-indazole-3- 
carboxamide 
C24H21FN4O2 416.5 1 




C21H22FN3O3 383.4 1 




C24H28N4O2 404.5 1 
Cyclohexylphenol 










C25H38O3 386.567 5 




C23H34O3 358.513 1 




C25H38O2 370.567 1 
JWH-133 No information (6aR,10aR)-3-(1,1- 
Dimethylbutyl)-6a,7,10,10a-  
tetrahydro -6,6,9-trimethyl-6H- 
dibenzo [b, d] pyran 
C22H32O 312.489 1 
O-2545 No information 6a,7,10,10a-tetrahydro-3- 
[5-(1H-imidazol-1-yl)-1,1-  
dimethylpentyl]- 
6,6,9-trimethyl-6H-dibenzo [b, d]  
pyran-1-ol,monohydrochloride 
C26H36N2O2 • 445 1 
Cannabicyclohexanol 
Cannabicyclohexanol CP 47497 dimethyloctyl  




(2- methylnonan-2-yl) phenol 
C22H36O2 332.5 3 
CP 47,497 (C7)-CP 47,479 rel-5-(1,1-dimethyl 
heptyl)-2-[(1R,3S)-3-  
hydroxycyclohexyl]-phenol 
C21H34O2 318.5 3 




C24H40O3 376.573 3 
Naphtoylpyrrole 
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JWH-307 No information (5-(2-fluorophenyl)-1- 
pentylpyrrol-3-yl)-naphthalen-1-  
ylmethanone 
C26H24FNO 385.472 1 
Naphthylmethylindene 
CB-13 CRA13, SAB-378 naphthalen-1-yl-(4- 
pentyloxynaphthalen-1-yl)methanone 
C26H24O2 368.467 3 
Indane 




C20H21F3O5S 430.437 1 
FAAH inhibitor 
URB-597 KDS-4103 (3'-(aminocarbonyl)  
[1,1'-biphenyl]-3-yl)-cyclohexyl  
carbamate 
C20H22N2O3 338.4 1 
Diarylpyrazole 






C22H21Cl3N4O 463.8 1 

















Table 3. Reports of SC derivatives per year 
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SC N 2004 2009 2010 2011 2012 2013 2014 2015 2016 
AM2201 125                   
JWH018 107                   
UR-144 63                   
5FAKB48 59                   
AB-
Fubinaca 
42                   
JWH073 38                   
JWH250 37                   
JWH122 32                   
JWH210 32                   
MAM2201 30                   
THJ018 30                   
5F-UR-144 29                   





















Table 4. SC-related blends reported by more than 10 users 
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Blend Synonyms Derivatives included N 
Spice Spice Gold, Spice 
Silver 
AM2201, CP47497, 
HU210, JWH derivatives, 
JWH018, JWH019, 
JWH073 and JWH122 
80 
K2 K2 Space Cadet, K2  
Summit, K2 Blonde, 
K2 Bubble Gum 
Flavour and Strong 
K2.  




Kosh Mr Kosh Apple,  
Mr Kosh Blueberry, 
Mr Kosh Double 
Blueberry, Mr Kosh 
Grape, Mr Kosh 
Potpourri, Mr Kosh 
Raspberry, Mr Kosh 
Strawberry and Mr 
Kosh Watermelon.  
NR 33 
Kronic Kronic Purple Haze, 
Kronic Black Label 






















Table 5. Routes of administration of SCs  
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Smoking 5FAKB48, AM2201,  
JWH019 
Spice, K2 ,  
Kronic 
Smoking SC/mixtures in 
bongs, pipes,  
rolling a drug into a joint, 
blunt or spliff, Smoking a 
cigarette dipped in SC 
powder. 
0.5 -500 0.5 - 40 2 – 270 540 






capsule, pellet, pill.  
Drinking powder 
dissolved in alcohol or 
other liquid. 
Eating Food with SC 
sprinkled onto it or baked 
with the food. 
0.1 - 400 10 - 210 20 – 960 99 
Sublingual AM-2201, AB-Chminaca, AB- 
Fubinaca, JWH-073, JWH-210, 
MAM-2201, UR-144 
NR Placing the SC powder  
or SC entrapped in a  
paper under the tongue 
5 - 50 60 150 – 300 7 
Nasal  
insufflation 
CP-47,497, JWH-018,  
WIN-55,212-2, XLR-11 
NR Snorting SC powder 2 - 60 NR NR 5 
Intraveous 2NE1, HU210, STS135 NR Injecting solution of SC 
derivative 
NR NR NR 3 
Rectal JWH073, UR144 NR Plugging SC derivative 
rectally in powder form 
3.5 mg NR NR 2 
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